Jason M. Foulks, Ph.D.
Affiliations: | 2007 | University of Utah, Salt Lake City, UT |
Area:
Pathology, Molecular BiologyGoogle:
"Jason Foulks"Parents
Sign in to add mentor| Thomas M. McIntyre | grad student | 2007 | University of Utah | |
| (The role of platelet activating factor acetylhydrolase in megakaryocytes and yeast.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sakemura RL, Hefazi M, Cox MJ, et al. (2023) AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells. Cancer Immunology Research |
| Chan TY, Egbert CM, Maxson JE, et al. (2021) TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications. 12: 5337 |
| Kumagai Y, Oishi J, Nakamura M, et al. (2019) Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer Cancer Research. 79: 3969-3969 |
| Mangelson R, Peterson P, Foulks JM, et al. (2019) Abstract 2197: The AXL kinase inhibitor, TP-0903, demonstrates efficacy in preclinical models of colorectal cancer independent of KRAS mutation status Cancer Research. 79: 2197-2197 |
| Zhang Y, Arner EN, Toombs JE, et al. (2019) Abstract C092: Axl inhibitor TP-0903 augments chemo- and immunotherapy efficacy in pancreatic cancer Molecular Cancer Therapeutics. 18 |
| Forostyan TV, Weagel E, Matsumura Y, et al. (2019) Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models Molecular Cancer Therapeutics. 18 |
| Pathi S, Peterson P, Mangelson R, et al. (2019) Abstract B080: PKM2 activation modulates metabolism and enhances immune response in solid tumor models Molecular Cancer Therapeutics. 18 |
| Tyagi E, Whatcott C, Foulks JM, et al. (2018) The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma Blood. 132: 3269-3269 |
| Sakemura R, Yang N, Cox MJ, et al. (2018) Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies Blood. 132: 728-728 |
| Xu Y, Brenning BG, Kultgen SG, et al. (2015) Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors. Acs Medicinal Chemistry Letters. 6: 63-7 |